-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
GlaxoSmithKline and its partner Vir Biotechnology are ramping up production of its COVID-19 antibody treatment sotrovimab at a second plant to keep up with surging demand
.
The rapid emergence of Omicron variants has added further pressure to supply, which has rendered competing antibodies from Regeneron Pharmaceuticals and Eli Lilly largely ineffective
COVID-19
Sotrovimab is approved in several countries, including the U.
S.
, for high-risk patients with mild to moderate COVID-19
.
Since the appearance of Omicron in late November, GlaxoSmithKline and Vir have released data from preclinical studies showing that sotrovimab retains in vitro activity against Omicron's spike protein, despite numerous mutations in the strain
Since the appearance of Omicron in late November, GlaxoSmithKline and Vir have released data from preclinical studies showing that sotrovimab retains in vitro activity against Omicron's spike protein, despite numerous mutations in the strain
A factory operated by WuXi AppTec in Shanghai has been responsible for the manufacture of sotrovimab, but since the advent of Omicron, GlaxoSmithKline and Vir have accelerated production by adding another factory operated by Samsung Biologics
.
However, while the Samsung factory is already ramping up global supply, it could take several months for it to operate at full capacity
Another pressure on supply is that Omicron has been found to evade a number of other monoclonal antibodies against COVID-19, including Regeneron's REGEN-COV and Eli Lilly's bamlanivimab in combination with etesevimab
.
In a recently updated COVID-19 treatment guideline , the National Institutes of Health (NIH) now recommends against the use of antibody therapies from Regeneron and Eli Lilly, given Omicron's dominance around the world
guide
Despite the new recommendations, some U.
S.
states with scarce supplies of monoclonal antibodies continue to use these two newly ineffective treatments
.
A recent analysis of federal data found that Regeneron and Eli Lilly have the highest rates of use of antibody therapies in more than a dozen states, including Florida, California and New York
Original source:
Original source:https://firstwordpharma.
https://firstwordpharma.
com/story/5485063 https://firstwordpharma.
com/story/5485063 Leave a comment here
